Valuation: Insulet Corporation

Market Cap 10.31B 9.08B 8.37B 7.83B 14.67B 972B 14.95B 101B 38.98B 479B 38.72B 37.88B 1,668B P/E 2026 *
24x
P/E 2027 * 18.7x
Enterprise Value 10.41B 9.17B 8.46B 7.91B 14.82B 981B 15.09B 102B 39.36B 484B 39.09B 38.25B 1,684B EV / Sales 2026 *
3.13x
EV / Sales 2027 * 2.55x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insulet Corporation

1 day+3.46%
1 week+3.73%
Current month+2.72%
1 month-3.87%
3 months-33.98%
6 months-48.45%
Current year-47.62%
1 week 138.79
Extreme 138.79
149.62
1 month 138.79
Extreme 138.79
161.35
Current year 138.79
Extreme 138.79
299.8
1 year 138.79
Extreme 138.79
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 27.62
Extreme 27.6201
354.88
Manager TitleAgeSince
Chief Executive Officer 55 2025-04-27
Director of Finance/CFO 53 2025-09-29
Compliance Officer 50 2022-11-30
Director TitleAgeSince
Chairman 61 2018-12-31
Director/Board Member 61 2015-07-26
Director/Board Member 59 2017-08-09
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

2,790 0.0040%
06-02Sell

Director

-418 0.0006%
06-02Buy

Director

3,450 0.0049%
Change 5-day change 1-year change 3-year change Capi.($)
+3.46%+3.73%-52.11%-48.28% 10.31B
-0.04%+2.25%-34.47%-16.25% 158B
-0.62%+2.55%-6.91%-8.40% 103B
-0.87%-8.40%+52.17%+56.27% 54.49B
+1.20%+2.66%-3.28%+51.58% 55.35B
+2.68%+4.35%-13.87%-42.40% 40.72B
+2.12%-1.02% - - 30.48B
+1.20%-2.08%-20.35%-44.97% 26.91B
+1.20%+5.20%+52.87%-7.25% 24.05B
+0.43%-2.90%-18.20%-3.56% 19.91B
Average +1.28%-0.19%-4.91%-7.03% 52.24B
Weighted average by Cap. +0.83%+0.80%-8.58%-2.40%

Financials

2026 *2027 *
Net sales 3.32B 2.93B 2.7B 2.52B 4.73B 313B 4.82B 32.43B 12.56B 155B 12.48B 12.21B 538B 3.94B 3.47B 3.2B 2.99B 5.6B 371B 5.71B 38.42B 14.88B 183B 14.78B 14.46B 637B
Net income 432M 380M 351M 328M 615M 40.73B 626M 4.22B 1.63B 20.09B 1.62B 1.59B 69.9B 565M 498M 459M 429M 804M 53.26B 819M 5.51B 2.14B 26.28B 2.12B 2.08B 91.42B
Net Debt 101M 88.62M 81.74M 76.45M 143M 9.49B 146M 982M 380M 4.68B 378M 370M 16.28B -285M -251M -231M -216M -405M -26.84B -413M -2.78B -1.08B -13.24B -1.07B -1.05B -46.07B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
26-06-24 US$148.88 +3.46% 1,404,142
26-06-23 US$143.90 +3.55% 1,854,938
26-06-22 US$138.97 -4.66% 1,685,321
26-06-18 US$145.76 +1.56% 2,864,144
26-06-17 US$143.52 -2.82% 1,542,221
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
148.88USD
Average target price
240.25USD
Spread / Average Target
+61.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock